Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 12 studies | 49% ± 25% | |
GABAergic neuron | 7 studies | 51% ± 26% | |
interneuron | 6 studies | 43% ± 22% | |
neuron | 5 studies | 29% ± 8% | |
retina horizontal cell | 5 studies | 46% ± 6% | |
granule cell | 4 studies | 54% ± 18% | |
oligodendrocyte precursor cell | 4 studies | 23% ± 7% | |
pancreatic A cell | 3 studies | 38% ± 7% | |
endothelial cell | 3 studies | 41% ± 15% | |
GABAergic interneuron | 3 studies | 37% ± 2% | |
astrocyte | 3 studies | 36% ± 22% | |
amacrine cell | 3 studies | 26% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 78% | 1929.34 | 2067 / 2642 | 31% | 0.87 | 217 / 705 |
pancreas | 30% | 78.03 | 99 / 328 | 16% | 0.66 | 28 / 178 |
adrenal gland | 3% | 9.67 | 9 / 258 | 34% | 2.14 | 78 / 230 |
prostate | 13% | 28.40 | 31 / 245 | 5% | 0.10 | 27 / 502 |
spleen | 11% | 32.85 | 27 / 241 | 0% | 0 | 0 / 0 |
stomach | 4% | 8.67 | 14 / 359 | 1% | 0.06 | 4 / 286 |
breast | 0% | 0.34 | 1 / 459 | 3% | 0.11 | 35 / 1118 |
intestine | 0% | 0.96 | 4 / 966 | 2% | 0.05 | 13 / 527 |
liver | 0% | 0 | 0 / 226 | 3% | 0.16 | 11 / 406 |
lung | 0% | 0.57 | 2 / 578 | 2% | 0.08 | 26 / 1155 |
skin | 3% | 6.09 | 46 / 1809 | 0% | 0 | 0 / 472 |
uterus | 0% | 0 | 0 / 170 | 2% | 0.04 | 9 / 459 |
esophagus | 1% | 1.18 | 9 / 1445 | 1% | 0.11 | 2 / 183 |
kidney | 1% | 2.46 | 1 / 89 | 0% | 0.01 | 4 / 901 |
bladder | 0% | 0 | 0 / 21 | 1% | 0.03 | 4 / 504 |
blood vessel | 1% | 1.07 | 7 / 1335 | 0% | 0 | 0 / 0 |
adipose | 0% | 1.12 | 6 / 1204 | 0% | 0 | 0 / 0 |
ovary | 0% | 0 | 0 / 180 | 0% | 0.01 | 2 / 430 |
thymus | 0% | 0.33 | 1 / 653 | 0% | 0.00 | 1 / 605 |
muscle | 0% | 0.18 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0034765 | Biological process | regulation of monoatomic ion transmembrane transport |
GO_0006813 | Biological process | potassium ion transport |
GO_1990573 | Biological process | potassium ion import across plasma membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005886 | Cellular component | plasma membrane |
GO_0008076 | Cellular component | voltage-gated potassium channel complex |
GO_0015467 | Molecular function | G-protein activated inward rectifier potassium channel activity |
GO_0005515 | Molecular function | protein binding |
GO_0005242 | Molecular function | inward rectifier potassium channel activity |
Gene name | KCNJ6 |
Protein name | G protein-activated inward rectifier potassium channel 2 (GIRK-2) (BIR1) (Inward rectifier K(+) channel Kir3.2) (KATP-2) (Potassium channel, inwardly rectifying subfamily J member 6) |
Synonyms | GIRK2 KCNJ7 KATP2 |
Description | FUNCTION: This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. |
Accessions | ENST00000645093.1 P48051 ENST00000609713.2 |